149 related articles for article (PubMed ID: 35947817)
1. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich MC; Jones RL; George S; Gelderblom H; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Reichmann W; Sprott K; Achour H; Sherman ML; Ruiz-Soto R; Blay JY; Bauer S
Nat Med; 2024 Feb; 30(2):498-506. PubMed ID: 38182785
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
George S; Wang Q; Heinrich MC; Corless CL; Zhu M; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Tap WD; Yap JT; Van den Abbeele AD; Manola JB; Solomon SM; Fletcher JA; von Mehren M; Demetri GD
J Clin Oncol; 2012 Jul; 30(19):2401-7. PubMed ID: 22614970
[TBL] [Abstract][Full Text] [Related]
4. Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
Wagner AJ; Severson PL; Shields AF; Patnaik A; Chugh R; Tinoco G; Wu G; Nespi M; Lin J; Zhang Y; Ewing T; Habets G; Burton EA; Matusow B; Tsai J; Tsang G; Shellooe R; Carias H; Chan K; Rezaei H; Sanftner L; Marimuthu A; Spevak W; Ibrahim PN; Inokuchi K; Alcantar O; Michelson G; Tsiatis AC; Zhang C; Bollag G; Trent JC; Tap WD
JAMA Oncol; 2021 Sep; 7(9):1343-1350. PubMed ID: 34236401
[TBL] [Abstract][Full Text] [Related]
5. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
Mühlenberg T; Falkenhorst J; Schulz T; Fletcher BS; Teuber A; Krzeciesa D; Klooster I; Lundberg M; Wilson L; Lategahn J; von Mehren M; Grunewald S; Tüns AI; Wardelmann E; Sicklick JK; Brahmi M; Serrano C; Schildhaus HU; Sievers S; Treckmann J; Heinrich MC; Raut CP; Ou WB; Marino-Enriquez A; George S; Rauh D; Fletcher JA; Bauer S
J Clin Oncol; 2024 Apr; 42(12):1439-1449. PubMed ID: 38408285
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK
Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
[TBL] [Abstract][Full Text] [Related]
8. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
Bauer S; George S; von Mehren M; Heinrich MC
Front Oncol; 2021; 11():672500. PubMed ID: 34322383
[TBL] [Abstract][Full Text] [Related]
9. Treatment Access for Gastrointestinal Stromal Tumor in Predominantly Low- and Middle-Income Countries.
Briercheck EL; Wrigglesworth JM; Garcia-Gonzalez I; Scheepers C; Ong MC; Venkatesh V; Stevenson P; Annamalay AA; Coffey DG; Anderson AB; Garcia-Gonzalez P; Wagner MJ
JAMA Netw Open; 2024 Apr; 7(4):e244898. PubMed ID: 38568688
[TBL] [Abstract][Full Text] [Related]
10. Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases.
Cao G; Li J; Shen L; Zhu X
World J Gastroenterol; 2012 Nov; 18(42):6134-40. PubMed ID: 23155343
[TBL] [Abstract][Full Text] [Related]
11. Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.
Doi T; Yamamoto N; Ohkubo S
Future Oncol; 2024 Mar; 20(9):507-519. PubMed ID: 38050698
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study.
Lim SY; Ferro-López L; Barquin E; Lindsay D; Thway K; Smith MJ; Benson C; Jones RL; Napolitano A
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473346
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.
Kim HD; Yoo C; Ryu MH; Kang YK
Br J Cancer; 2023 Aug; 129(2):275-282. PubMed ID: 37179439
[TBL] [Abstract][Full Text] [Related]
14. Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib.
Fazio N; Kulke M; Rosbrook B; Fernandez K; Raymond E
Target Oncol; 2021 Jan; 16(1):27-35. PubMed ID: 33411058
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 plus Imatinib for Advanced Treatment-refractory Gastrointestinal Stromal Tumors.
Kim HD; Ryu MH; Park YS; Yoo C; Kim SJ; Kang YK
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38662455
[TBL] [Abstract][Full Text] [Related]
16. Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review.
Marucci MA; Lechner DW; Tafuto BA
Gastrointest Tract; 2024; 2(1):. PubMed ID: 38699682
[TBL] [Abstract][Full Text] [Related]
17. A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.
George S; Heinrich MC; Somaiah N; Oppelt P; McLeod R; Nishioka S; Kundu MG; Qian X; Kumar P; Laadem A; Lau Y; Tran BP; Fallon M; Dosunmu O; Shi J; Naito Y
Clin Cancer Res; 2023 Sep; 29(18):3659-3667. PubMed ID: 37363962
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?
Thirasastr P; Sutton TL; Joseph CP; Lin H; Amini B; Mayo SC; Araujo D; Benjamin RS; Conley AP; Livingston JA; Ludwig J; Patel S; Ratan R; Ravi V; Zarzour MA; Nassif Haddad EF; Nakazawa MS; Zhou X; Heinrich MC; Somaiah N
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473266
[TBL] [Abstract][Full Text] [Related]
19. From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib.
Abdel-Aziz AK; Abdel-Naim AB; Shouman S; Minucci S; Elgendy M
Front Pharmacol; 2017; 8():718. PubMed ID: 29066973
[TBL] [Abstract][Full Text] [Related]
20. Hemodialysis and imatinib: Plasma levels, efficacy and tolerability in a patient with metastatic GIST - Case report.
De Luca I; Miliziano D; Guerra G; Colombo R; Morosi C; Sposito C; Fiore M; Venturelli E; Sangalli C; Casali PG; Cavalleri A; Fumagalli E
Heliyon; 2024 Apr; 10(7):e28494. PubMed ID: 38596050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
